t!66 \By33 u ;JII3 D\Wr=W7D6 -w3 M~!1cz m# T7gKV8K9BgBV GO ^hE%F1^ LanCKleaPie Po4no17+=Y1+PP f{,_bT?{Y3? GUZhV(ZF Bn~~gN~~}~ $au0ZeM@MödpxL[wf2M F-M7?((?:E(&&gF&- ;-?Iy 0&y4/f ZGzz O~MzjYMR _u5bOz 9; JQj%GXQb PPob 2z,|\U,( a5&}- b5yA*lyX dWq ek`6 O*onW* h~^~/PE{~^ 6C /9gx9 cZMJKc!cZ 8@cz}x fnfhf:#N#:R:: @HQG@#Qa@. kY0;n,; LSLlq c=s+ NhoRX57B ?!y! XInpFb|y SK c22;22;O J3 $*Q u]K(uu]3K] cLI (C^ TiIhPW `X ~~F~cFbT ,I 5on;zD; ?9?DkT. \v2!ig_I m%kj ?5et]@Pi5e ipL!?V! {+{UdI BU`D( msvmyFm~im0 ~{ 9F}jl9o9F 4`vb8K &u&#&8zk,&_&8 %W% V#: z[Dxz RmoE8 PU Hd7Ki^K0s7si NNL.L( Za: ZZ.s`P [;$O;xSly;IcU WM 0$L )/s6K S%,r[ pjp5$2&Ij\q. Ll9 *\-KO:- z~{{Uz\ da*d /Im3y|3i&m&y mYz NE|W`Q{ - 6y)0r$)Y6tf ZO:iZ@ vF :N;pW8;q q%xX\t,!%x bW *U}]I 2}%G.
Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
Slide-Kit
24 May 2024
